The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia

Schizophrenia Bulletin

Volumn 26, Issue 2, 2000, Pages 441-449

  Drake, Robert E ^a,b   Xie, Haiyi ^d   McHugo, Gregory J ^d   Green, Alan I ^c  

^a DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NONE

Author keywords

Clozapine; Schizophrenia; Substance abuse; Substance use disorder

Indexed keywords

ALCOHOL; CANNABIS; CLOZAPINE; COCAINE; ILLICIT DRUG;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0033918990     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033464     Document Type: Article

References (43)

1. Albanese, M.J.; Khantzian, E.J.; Murphy, S.L.; and Green, A.I. Decreased substance use in chronically psychotic patients treated with clozapine. [Letter]. American Journal of Psychiatry, 151:780-781, 1994.
2. Buckley, P.; Thompson, P.; Way, L.; and Meltzer, H.Y. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. American Journal of Psychiatry, 151:385-389, 1994.
3. Carey, K.B. Reliability and validity of the Time-Line Follow-Back Interview among psychiatric outpatients: A preliminary report. Psychology of Addictive Behaviors, 11:26-33, 1997.
4. Carey, K.B.; Cocco, K.M.; and Correia, C.J. Reliability and validity of the Addiction Severity Index among outpatients with severe mental illness. Psychological Assessment, 9:422-428, 1997.
5. Carey, K.B.; Cocco, K.M.; and Simons, J.S. Concurrent validity of clinicians' ratings of substance abuse among psychiatric outpatients. Psychiatric Services, 47:842-847, 1996.
6. Chouljian, T.L.; Shumway, M.; Balancio, E.; Dwyer, E.V.; Surber, R.; and Jacobs, M. Substance use among schizophrenic outpatients: Prevalence, course, and relation to functional status. Annals of Clinical Psychiatry, 7:19-24, 1995.
7. Clark, R.E.; Teague, G.B.; Rickets, S.J.; Bush, P.W.; Xie, H.; McGuire, T.G.; Drake, R.E.; McHugo, G.J.; Keller, A.M.; and Zubkoff, M. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders. Health Services Research, 33:1283-1306, 1998.
8. Cournos, F.; Empfield, M.; Horwath, E.; McKinnon, K.; Meyer, I.; Schrage, H.; Currie, C.; and Agosin, B. HIV seroprevalence among patients admitted to two psychiatric hospitals. American Journal of Psychiatry, 148:1225-1230, 1991.
9. Cuffel, B.J.; Shumway, M.; Chouljian, T.L.; and MacDonald, T. A longitudinal study of substance abuse and community violence in schizophrenia. Journal of Nervous and Mental Disease, 182:704-708, 1994.
10. Drake, R.E.; McHugo, G.J.; Clark, R.E.; Teague, G.B.; Xie, H.; Miles, K.; and Ackerson, T.H. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder. A clinical trial. American Journal of Orthopsychiatry, 68:201-215, 1998a.
11. Drake, R.E.; Mercer-McFadden, C.; Mueser, K.T.; McHugo, G.J.; and Bond, G.R. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophrenia Bulletin, 24(4):589-608, 1998b.
12. Drake, R.E.; Mueser, K.T.; and McHugo, G.J. Using clinician rating scales to assess substance abuse among persons with severe mental disorders. In: Sederer, L.I., and Dickey, B., eds. Outcomes Assessment in Clinical Practice. Baltimore, MD: Williams and Wilkins, 1995. pp. 113-116.
13. Drake, R.E.; Osher, F.C.; Noordsy, D.L.; Hurlbut, S.C.; Teague, G.B.; and Beaudett, M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin, 16(1):57-67, 1990a.
14. Drake, R.E.; Osher, F.C.; and Wallach, M.A. Alcohol use and abuse in schizophrenia. A prospective community study. Journal of Nervous and Mental Disease, 177:408-414, 1989.
15. Drake, R.E.; Teague, G.B.; and Warren, S.R. New Hampshire's dual diagnosis program for people with severe mental illness and substance abuse. Addiction and Recovery, 10:35-39, 1990b.
16. George, T.P.; Sernyak, M.J.; Ziedonis, D.M.; and Woods, S.W. Effects of clozapine on smoking in chronic schizophrenic outpatients. Journal of Clinical Psychiatry, 56:344-346, 1995.
17. Goldfinger, S.M.; Schutt, R.K.; Seidman, L.J.; Turner, W.M.; Penk, W.E.; and Tolomiczenko, G.S. Self-report and observer measures of substance abuse among homeless mentally ill persons in the cross-section and over time. Journal of Nervous and Mental Disease, 184:667-672, 1996.
18. Green, A.I.; Zimmet, S.V.; Strous, R.D.; and Schildkraut, J.J. Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Review of Psychiatry, 6:287-296, 1999.
19. Jennrich, R.I., and Schluchter, M.D. Unbalanced repeated-measures models with structured covariance matrices. Biometrics, 42:805-820, 1986.
20. Kane, J.; Honigfeld, G.; Singer, J.; and Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
21. Khantzian, E.J. The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. [Review]. Harvard Review of Psychiatry, 4:231-244, 1997.
22. Linszen, D.H.; Dingemans, P.M.; and Lenoir, M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51:273-279, 1994.
23. Litten, R.Z.; Allen, J.; and Fertig, J. Pharmacotherapies for alcohol problems: A review of research with focus on developments since 1991. Alcoholism, Clinical and Experimental Research, 20:859-876, 1996.
24. Lukoff, D.; Nuechterlein, K.H.; and Ventura, J. Appendix A: Manual for expanded Brief Psychiatric Rating Scale (BPRS). Schizophrenia Bulletin, 12(4):594-602, 1986.
25. Marcus, P., and Snyder, R. Reduction of comorbid substance abuse with clozapine. [Letter]. American Journal of Psychiatry, 152:959, 1995.
26. McEvoy, J.P.; Freudenreich, O.; Levin, E.D.; and Rose, J.E. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology, 119:124-126, 1995a.
27. McEvoy, J.; Freudenreich, O.; McGee, M.; VanderZwaag, C.; Levin, E.; and Rose, J. Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry, 37:550-552, 1995b.
28. McHugo, G.J.; Drake, R.E.; Burton, H.L.; and Ackerson, T.H. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. Journal of Nervous and Mental Disease, 183:762-767, 1995.
29. McLean, R.A.; Sanders, W.L.; and Stroup, W.W. A unified approach to mixed linear models. American Statistician, 45:54-64, 1991.
30. McLellan, A.T.; Luborsky, L.; Woody, G.E.; and O'Brien, C.P. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous and Mental Disease, 168:26-33, 1980.
31. Meltzer, H.Y. An overview of the mechanism of action of clozapine. Journal of Clinical Psychiatry, 55(Suppl B):47-52, 1994.
32. Mueser, K.T.; Curran, P.J.; and McHugo, G.J. Factor structure of the Brief Psychiatric Rating Scale in schizophrenia. Psychological Assessment, 9:196-204, 1997.
33. Regier, D.A.; Farmer, M.E.; Rae, D.S.; Locke, B.Z.; Keith, S.J.; Judd, L.L.; and Goodwin, F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 264:2511-2518, 1990.
34. Richelson, E. Preclinical pharmacology of neuroleptics: Focus on new generation compounds. Journal of Clinical Psychiatry, 57(Suppl 11):4-11, 1996.
35. Siris, S.G. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophrenia Bulletin, 16(1):111-122, 1990.
36. Sobell, M.B.; Maisto, S.A.; Sobell, L.C.; Cooper, A.M.; Cooper, T.; and Sanders, B. Developing a prototype for evaluating alcohol treatment effectiveness. In: Sobell, L.C.; Sobell, M.B.; and Ward, E., eds. Evaluating Alcohol and Drug Treatment Effectiveness. New York, NY: Pergamon, 1980. pp. 129-150.
37. Spitzer, R.L.; Williams, J.B.W.; Gibbon, M.; and First, M.B. Structured Clinical Interview for DSM-III-R. New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 1988.
38. Swofford, C.D.; Kasckow, J.W.; Scheller-Gilkey, G.; and Inderbitzin, L.B. Substance abuse: A powerful predictor of relapse in schizophrenia. Schizophrenia Research, 20:145-151, 1996.
39. Teague, G.B.; Drake, R.E.; and Ackerson, T.H. Evaluating use of continuous treatment teams for persons with mental illness and substance abuse. Psychiatric Services, 46:689-695, 1995.
40. Voruganti, L.N.; Heslegrave, R.J.; and Awad, A.G. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. Journal of Nervous and Mental Disease, 185:463-465, 1997.
41. Wolford, G.L.; Rosenberg, S.D.; Oxman, T.E.; Drake, R.E.; Mueser, K.T.; Oxman, I.E.; Hoffman, D.; Vidaver, R.M.; Luckoor, R.; and Carrieri, K.L. Evaluation of methods for detecting substance use disorder in persons with severe mental illness. Psychology of Addictive Behaviors, 13:313-326, 1999.
42. Yovell, Y., and Opler, L.A. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: A case report and a hypothesis. Journal of Nervous and Mental Disease, 182:591-592, 1994.
43. Zimmet, S.V.; Strous, R.D.; Burgess, E.S.; Kohnstamm, S.; and Green, A.I. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. Journal of Clinical Psychopharmacology, 20:94-98, 2000.